Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Director · CEO | March 05, 2025 | March 07, 2025 |
| Social Capital Suvretta Holdings Corp. IVDNAD · Entity 123913 | Director | September 07, 2022 | September 09, 2022 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | December 09, 2020 | December 11, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUTRO BIOPHARMA, INC.
Report date March 05, 2025 · Filed March 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 292,531 |
Ending reported balance
After 2025-03-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-03-05 · Exercise / conversion · Acquired 18,750 · Balance 299,239 Row 2 · 2025-03-05 · Tax withholding · Disposed 6,708 · Balance 292,531 F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2025-03-05 | Direct | 0 |
Reported balance
After 2025-03-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-03-05 · Exercise / conversion · Disposed 18,750 · Balance 0 F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy William J. Newell Family Trust DTD 03/15/2019 | 116,525 |
Reported balance
Holding disclosure · report date 2025-03-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 116,525 F2: The securities are held of record by the reporting person as trustee of the William J. Newell Family Trust DTD 03/15/2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2: The securities are held of record by the reporting person as trustee of the William J. Newell Family Trust DTD 03/15/2019.
F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F4: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date.
Social Capital Suvretta Holdings Corp. IV
Report date September 07, 2022 · Filed September 09, 2022
This filing explicitly reported no securities owned.
Vaxcyte, Inc.
Report date December 09, 2020 · Filed December 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,684 |
Reported balance
After 2020-12-09 transaction · row 1
1 source rowRow 1 · 2020-12-09 · Grant · Acquired 22,228 · Balance 66,684 F1: Shares acquired by the reporting person from Sutro Biopharma, Inc. pursuant to the Sutro Biopharma, Inc. 2017 Call Option Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired by the reporting person from Sutro Biopharma, Inc. pursuant to the Sutro Biopharma, Inc. 2017 Call Option Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2021 Filed Sep 28, 2021 18:58 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GiftCommon Stock | 104,662 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057981 · doc4.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By William J. Newell Family Trust DTD 03/15/2019 Disclosed balance after: 104,662 F1 · ownership.nature: The securities are held of record by the reporting person as trustee of the William J. Newell Family Trust DTD 03/15/2019. Read SEC document |
| July 01, 2021 Filed Sep 28, 2021 18:58 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GiftCommon Stock | 104,662 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057981 · doc4.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,687 Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 17:20 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018623 · doc4.xml · derivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2025-03-05 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 17:20 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 200,000 | $0.00 Strike: $21.11 | $0.00 |
DisclosureSEC source: 0001209191-21-018623 · doc4.xml · derivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-03-04 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on April 5, 2021, with 100% of the total shares vested and exercisable on March 5, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 17:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006559 · doc4.xml · derivative · entry 5 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,250 Underlying: Common Stock · 13,750 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 17:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 7,061 | $22.15 | $156,401.15 |
DisclosureSEC source: 0001209191-21-006559 · doc4.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,349 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 17:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006559 · doc4.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 01:39 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 22,228 | $1.29 | $28,674.12 |
DisclosureSEC source: 0001209191-20-062813 · doc4.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,684 F1 · kind: Shares acquired by the reporting person from Sutro Biopharma, Inc. pursuant to the Sutro Biopharma, Inc. 2017 Call Option Plan. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:57 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 25,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052248 · doc4.xml · derivative · entry 5 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,253 Underlying: Common Stock · 25,252 shares Expires 2021-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:57 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 13,219 | $10.30 | $136,155.70 |
DisclosureSEC source: 0001209191-20-052248 · doc4.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,660 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:57 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 25,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052248 · doc4.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 22:19 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036742 · doc4.xml · derivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: 1/3 of the shares subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter. Read SEC document |
| May 14, 2020 Filed May 14, 2020 17:29 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | PurchaseCommon Stock | 64,516 | $7.75 | $499,999.00 |
DisclosureSEC source: 0001209191-20-029246 · doc4.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,627 Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 17:20 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005814 · doc4.xml · derivative · entry 5 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2024-01-29 F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 17:20 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 125,000 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001209191-20-005814 · doc4.xml · derivative · entry 4 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-01-29 F4 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 29, 2020, with 100% of the total shares vested and exercisable on January 29, 2024, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:26 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 25,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051124 · doc4.xml · derivative · entry 5 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,505 Underlying: Common Stock · 25,252 shares Expires 2021-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F7 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:26 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 13,219 | $9.74 | $128,753.06 |
DisclosureSEC source: 0001209191-19-051124 · doc4.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,118 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 17:26 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 25,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051124 · doc4.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Since the date of the reporting person's last ownership report, he transferred 94,085 shares of the issuer's common stock in a transfer exempt from Section 16. Following this transfer, the reporting person does not have voting or investment power over, or a pecuniary interest in, the transferred shares. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 17:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 445,000 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-19-006206 · doc4.xml · derivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,000 Underlying: Common Stock · 445,000 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on February 28, 2019, with 100% of the total shares vested and exercisable on January 29, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:20 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionSeries B Preferred Stock · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052841 · doc4.xml · derivative · entry 7 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · By Newell Family Revocable Trust DTD 08/14/2008 Disclosed balance after: 0 Underlying: Common Stock · 2,890 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · ownership.nature: These securities are held of record by the reporting person as trustee of the Newell Family Revocable Trust DTD 08/14/2008. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:20 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionSeries D Preferred Stock · Derivative | 192,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052841 · doc4.xml · derivative · entry 6 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,787 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · derivative.exercise_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · derivative.expiration_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:20 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionSeries C Preferred Stock · Derivative | 55,657 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052841 · doc4.xml · derivative · entry 5 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,059 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:20 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionCommon Stock | 2,890 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052841 · doc4.xml · nonDerivative · entry 3 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · By Newell Family Revocable Trust DTD 08/14/2008 Disclosed balance after: 21,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · ownership.nature: These securities are held of record by the reporting person as trustee of the Newell Family Revocable Trust DTD 08/14/2008. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:20 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionCommon Stock | 7,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052841 · doc4.xml · nonDerivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. Read SEC document |
| October 01, 2018 Filed Oct 1, 2018 17:20 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionCommon Stock | 2,059 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052841 · doc4.xml · nonDerivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 18:03 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 75,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052492 · doc4.xml · derivative · entry 2 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,757 Underlying: Common Stock · 75,757 shares Expires 2021-09-25 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 18:03 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 454,545 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052492 · doc4.xml · derivative · entry 1 NEWELL WILLIAM J · CIK 0001309660 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,545 Underlying: Common Stock · 454,545 shares Expires 2028-09-25 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.